Abstract
Human immunodeficiency virus (HIV)-associated neurocognitive disorder (HAND) affects nearly half of the 39 million people living with HIV. HAND symptoms range fromsubclinical cognitive impairment to dementia; the mechanisms that underlie HAND remain unclear and there is no treatment. The HIV protein transactivator of transcription (TAT) is thought to contribute to HAND because it persists in the central nervous system and elicits neurotoxicity in animal models. Network hyperexcitability is associated with accelerated cognitive decline in neurodegenerative disorders. Here we show that the antiepileptic drug levetiracetam (LEV) attenuated aberrant excitatory synaptic transmission, protected synaptic plasticity, reduced seizure susceptibility, and preserved cognition in inducible TAT (iTAT) transgenic male mice. iTAT mice had an increased frequency of spontaneous excitatory postsynaptic currents in hippocampal slice recordings and impaired long-term potentiation, a form of synaptic plasticity that underlies learning and memory. Two-week administration of LEV by osmotic minipump prevented both impairments. Kainic acid administered to iTAT mice induced a higher maximum behavioral seizure score, longer seizure duration, and shorter latency to first seizure, consistent with a lower seizure threshold. LEV treatment prevented these in vivo signs of hyperexcitability. Lastly, in the Barnes maze, iTAT mice required more time to reach the goal, committed more errors, and received lower cognitive scores relative to iTAT mice treated with LEV. Thus, TAT expression drives functional deficits, suggesting a causative role in HAND. As LEV not only prevented aberrant synaptic activity in iTAT mice but also prevented cognitive dysfunction, it may provide a promising pharmacological approach to the treatment of HAND.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 104-118 |
| Number of pages | 15 |
| Journal | The Journal of pharmacology and experimental therapeutics |
| Volume | 391 |
| Issue number | 1 |
| Early online date | Jul 26 2024 |
| DOIs | |
| State | Published - Oct 1 2024 |
Bibliographical note
Publisher Copyright:© 2024 by The American Society for Pharmacology and Experimental Therapeutics.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
-
SDG 5 Gender Equality
Keywords
- AIDS Dementia Complex/drug therapy
- Animals
- Anticonvulsants/pharmacology
- Cognition/drug effects
- Disease Models, Animal
- Excitatory Postsynaptic Potentials/drug effects
- HIV-1/drug effects
- Hippocampus/drug effects
- Humans
- Levetiracetam/pharmacology
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Transgenic
- Neuronal Plasticity/drug effects
- Piracetam/analogs & derivatives
- Seizures/drug therapy
- Synaptic Transmission/drug effects
- tat Gene Products, Human Immunodeficiency Virus/genetics
PubMed: MeSH publication types
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
Fingerprint
Dive into the research topics of 'Levetiracetam Prevents Neurophysiological Changes and Preserves Cognitive Function in the Human Immunodeficiency Virus (HIV)-1 Transactivator of Transcription Transgenic Mouse Model of HIV-Associated Neurocognitive DisorderS'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS